Neuromyelitis Optica Treatment
Authors:
- Denis Bernardi BichuettiDBDenis Bernardi Bichuetti
- Enedina Maria Lobato de OliveiraEOEnedina Maria Lobato de Oliveira
- Daniel May OliveiraDODaniel May Oliveira
- Nilton Amorin de SouzaNSNilton Amorin de Souza
- Alberto Alain GabbaiAGAlberto Alain Gabbai
Open Access
- 1 September 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (9) , 1131-1136
Abstract
Neuromyelitis optica (NMO) (Devic disease) is an inflammatory autoimmune disease of the central nervous system that affects preferentially the optic nerve and spinal cord,1 distinct from multiple sclerosis (MS). Pathological study results obtained from patients with NMO have shown inflammation with macrophage predominance, perivascular granulocytes, eosinophils, immunoglobulin deposition, extensive axonal loss within the spinal cord, and optic nerve lesions.2 The recent identification of a specific antibody targeted to the blood-brain barrier water channel aquaporin 4 in patients with NMO (NMO-IgG) has turned it into a central nervous system autoimmune chanellopathy.3,4Keywords
This publication has 27 references indexed in Scilit:
- Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 PatientsYearbook of Neurology and Neurosurgery, 2010
- Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysisMultiple Sclerosis Journal, 2007
- Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)Neurological Sciences, 2007
- Neuromyelitis optica: Changing conceptsJournal of Neuroimmunology, 2007
- Immunosuppressive therapy is more effective than interferon in neuromyelitis opticaMultiple Sclerosis Journal, 2007
- Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)Archives of Neurology, 2006
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelJournal of Experimental Medicine, 2005
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004
- Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis OpticaJournal of Neurology, 2004